Healthequity Inc (HQY) Q4 2026 Earnings Call Transcript

Why It Matters

The results underscore HealthEquity’s ability to grow profitable scale while curbing fraud costs, positioning it to capture a larger share of a potentially expanding HSA market.

Key Takeaways

• Revenue rose 15% YoY to $1.1B.
• Adjusted EBITDA margin reached 42%, up one point.
• HSA assets hit $31B, 15% increase.
• Fraud costs fell to $3M, down from $11M.
• Guidance lifted, targeting $1.3B revenue FY2026.

Pulse Analysis

HealthEquity’s Q1 performance illustrates how a focused blend of fee‑based growth and operational efficiency can drive earnings in the health‑savings sector. The 15% revenue lift was powered primarily by custodial fees, which jumped 29%, and a 14% rise in interchange revenue, outpacing account growth. This fee‑centric model benefits from the rising popularity of HSAs and consumer‑direct benefits, especially as employers seek tax‑advantaged tools to offset rising healthcare costs. The company’s ability to expand HSA assets to $31 billion while maintaining a 68% gross margin signals strong pricing power and effective cost management.

A key differentiator for HealthEquity is its aggressive investment in artificial intelligence and security. AI‑driven claims adjudication, chat agents, and fraud detection have already cut fraud reimbursements from $11 million to $3 million in a single quarter, moving the company toward its goal of a one‑basis‑point fraud rate relative to total assets. The rollout of a secure mobile app with multi‑factor authentication not only enhances member trust but also drives higher engagement, as evidenced by 1.2 million downloads and increased transaction activity. These technology initiatives are expected to lower the cost‑to‑serve and support margin expansion in the coming years.

Legislative developments could further accelerate HealthEquity’s growth trajectory. Proposed House budget provisions aim to broaden HSA eligibility, potentially adding 20 million families and increasing contribution limits for lower‑income earners. If enacted, the expanded addressable market would reinforce HealthEquity’s near‑quarter‑share of U.S. HSAs and provide a tailwind for both organic acquisition and strategic M&A. Investors should weigh the company’s solid financial footing, rising cash flow, and share‑repurchase program against the uncertainty of legislative outcomes, but the current outlook suggests a compelling growth story for the health‑savings ecosystem.